Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P. Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J. Mease, Alan J. Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Objective. The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods. RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease. The assessed outcomes included ASAS20, ASAS40, AS DAS (ASDAS), BASDAI, BASFI and BASMI scores, along with selected measures of remission. Further patient-reported outcomes, peripheral arthritis, enthesitis, uveitis and quality-of-life measures are also reported. Results. Two hundred and eighteen of 325 patients randomized (AS: 121; nr-axSpA: 97) received certolizumab pegol from week 0. Of these, 65% remained in the study at week 204 (AS: 67%; nr-axSpA: 63%). Across all outcomes, for AS and nr-axSpA, sustained improvements were observed to week 204 [week 204 overall axSpA: ASAS20: 54.1% (non-responder imputation); 83.7% (observed case, OC); ASAS40: 44.0% (non-responder imputation); 68.1% (OC); ASDAS inactive disease: 32.1% (last observation carried forward); 31.4% (OC)]. In the safety set (n = 315), there were 292.8 adverse events and 10.4 serious adverse events per 100 patient-years. No deaths were reported. Conclusion. In the first study to evaluate the efficacy of an anti-TNF across both axSpA subpopulations, improvements in clinical and patient-reported outcomes at 24 and 96 weeks were sustained through 4 years of treatment, with no new safety signals.

Original languageEnglish (US)
Pages (from-to)1498-1509
Number of pages12
JournalRheumatology (United Kingdom)
Volume56
Issue number9
DOIs
StatePublished - Sep 1 2017

Keywords

  • Ankylosing spondylitis
  • Axial spondyloarthritis
  • Certolizumab pegol
  • Non-radiographic axial spondyloarthritis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA'. Together they form a unique fingerprint.

  • Cite this

    van der Heijde, D., Dougados, M., Landewé, R., Sieper, J., Maksymowych, W. P., Rudwaleit, M., Van den Bosch, F., Braun, J., Mease, P. J., Kivitz, A. J., Walsh, J., Davies, O., Bauer, L., Hoepken, B., Peterson, L., & Deodhar, A. (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (United Kingdom), 56(9), 1498-1509. https://doi.org/10.1093/rheumatology/kex174